Replimune Group, Inc. (REPL) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
High 13.18 at 11:30 am ET, low 12.80 at 8:15 am ET.
Replimune Group, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
the bull case· 4
7
disclosed supplier and customer ties reported in sec filings
sec filingsedgar4
funds on file reporting a position in REPL
n-portas of Jun 30 '26+26.34%
change in shares held by the ten largest reporting managers this quarter
13fJun 30 '26204
managers reporting a position in thirteen F filings
13fJun 30 '26the bear case· 4
8 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized4 of 22
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '2622
managers whose positions together make up four fifths of reported value
13fJun 30 '260.28%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Replimune Group, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
tall tick = annual report · 1 on record
204 managers report a position worth $1.2B between them, and 22 of them hold 80% of it.
REPL (Replimune Group, Inc.) has 7 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.